{"id":81981,"date":"2026-06-12T01:29:14","date_gmt":"2026-06-12T01:29:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/81981\/"},"modified":"2026-06-12T01:29:14","modified_gmt":"2026-06-12T01:29:14","slug":"experimental-alzheimers-drug-candidate-slowed-disease-progression-in-mice-and-appeared-to-slow-aging","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/81981\/","title":{"rendered":"Experimental Alzheimer&#8217;s Drug Candidate Slowed Disease Progression In Mice And Appeared To Slow Aging"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/Woman-puzzle-pieces-1200x800.jpg\" alt=\"Elderly woman working with puzzle\"\/><\/p>\n<p class=\"post-featured-image-caption\">(Credit: \u00a9 Robert Kneschke | Dreamstime.com)<\/p>\n<p>New Alzheimer\u2019s Drug Candidate Targets a Different Mechanism Than Existing Treatments<\/p>\n<p>In A Nutshell<\/p>\n<p>Scientists at ETH Zurich developed a compound called CPD10 that targets a protein called GRK2, which clogs the energy-generating structures inside brain cells and drives Alzheimer\u2019s-like damage.<\/p>\n<p>In Alzheimer\u2019s mice, CPD10 reduced brain damage, cut plaque buildup, extended survival, and appeared to slow aging, including less graying fur in treated animals.<\/p>\n<p>ETH Zurich is now seeking a pharmaceutical partner to advance CPD10 toward human development, calling it a potential new mechanism distinct from existing Alzheimer\u2019s treatments.<\/p>\n<p>All findings are from animal studies; CPD10 has not been tested in humans, and results in mice do not always translate to people.<\/p>\n<p class=\"wp-block-paragraph\">Most Alzheimer\u2019s drug development has focused on the same target: the sticky plaques that accumulate in the brain. A new study from ETH Zurich, the product of nearly 20 years of work, points to a different culprit operating deeper inside brain cells, and the experimental compound developed to address it did something researchers had not anticipated. Besides slowing disease progression in mice, it appeared to slow aging.<\/p>\n<p class=\"wp-block-paragraph\">Scientists at ETH Zurich and partner institutions found that GRK2, a protein that normally helps <a href=\"https:\/\/studyfinds.com\/superagers-bigger-brain-cells\/\" type=\"post\" id=\"77097\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">brain cells<\/a> survive and respond to stress, misfires badly in the Alzheimer\u2019s brain. When it malfunctions, it clumps into dysfunctional masses on the mitochondria, the tiny power-generating structures inside cells. Published in <a href=\"https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(26)00124-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126001242%3Fshowall%3Dtrue\" type=\"link\" id=\"https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(26)00124-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126001242%3Fshowall%3Dtrue\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Cell Reports Medicine<\/a>, the study shows that clumping sets off a chain reaction draining cellular energy, worsening the plaques that define Alzheimer\u2019s, and killing neurons.<\/p>\n<p class=\"wp-block-paragraph\">In the brains of aged <a href=\"https:\/\/studyfinds.com\/tag\/alzheimers\/\" type=\"post_tag\" id=\"442\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Alzheimer\u2019s<\/a> mice, more than 63% of GRK2 in the hippocampus, the brain region essential for memory, had clumped into dysfunctional masses, compared to less than 9% in healthy mice. Similar clumping also appeared in brain tissue from a small number of patients with dementia likely due to Alzheimer\u2019s, suggesting, but not proving, the process may occur in people.<\/p>\n<p>Defective GRK2 Clogs Brain Cell Power Plants and Accelerates Plaque Formation<\/p>\n<p class=\"wp-block-paragraph\">GRK2 exists in two forms: a normal, functioning version and a chemically altered, inactive form. In Alzheimer\u2019s, the disease\u2019s hallmark proteins, <a href=\"https:\/\/studyfinds.com\/buffer-against-alzheimers-on-brain-scan\/\" type=\"post\" id=\"154361\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">amyloid-beta<\/a> and tau, trigger a chemical change that inactivates GRK2 and causes it to clump. Those clumps migrate to the mitochondria, where they trap a second protein called TOMM6 and render it useless. \u201cThe GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells,\u201d Quitterer explains.<\/p>\n<p class=\"wp-block-paragraph\">That stress creates more amyloid-beta. More amyloid-beta triggers more inactive, clumped GRK2, which clamps down harder on the mitochondria. A feedback loop quietly accelerates the disease.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/grk2-infographic-1200x675.png\" alt=\"grk2 infographic\"  \/><\/p>\n<p>A new Alzheimer\u2019s compound works via a different mechanism than existing treatments and slowed aging in mice, a new study finds. (Image by StudyFinds)<\/p>\n<p>CPD10 Reduced Alzheimer\u2019s Damage in Mice and Slowed Cellular Aging<\/p>\n<p class=\"wp-block-paragraph\">To break that loop, Quitterer\u2019s team developed a compound they call Compound 10, or CPD10, engineered to stabilize the healthy form of GRK2 and clear out the dysfunctional clumps. It crossed into the <a href=\"https:\/\/studyfinds.com\/tag\/brain\/\" type=\"post_tag\" id=\"24\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">brain<\/a> effectively, reaching roughly the same concentration there as in the blood. After six months of treatment in Alzheimer\u2019s mice, CPD10 dramatically reduced GRK2 clumping on mitochondria, restored energy production, cut amyloid-beta plaques, and lowered markers of brain inflammation. Treated mice showed less nerve cell loss, better spatial memory, and longer survival than untreated Alzheimer\u2019s mice.<\/p>\n<p class=\"wp-block-paragraph\">More surprisingly, CPD10 appeared to slow aging beyond the brain. Treated mice showed improved <a href=\"https:\/\/studyfinds.com\/using-marijuana-regularly-may-change-structure-of-heart-impair-function\/\" type=\"post\" id=\"20026\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">heart function<\/a>, and in a striking detail, developed fewer gray hairs in old age than untreated animals. Consistent with that, the compound significantly reduced UPAR, a biological marker of cellular aging, in treated mice.<\/p>\n<p class=\"wp-block-paragraph\">A second compound, CPD57, targeted the cell\u2019s protein cleanup system, which malfunctions in Alzheimer\u2019s and lets damaged proteins pile up. Short-term treatment accelerated the breakdown of defective GRK2 clumps; six months of treatment reduced amyloid-beta plaques, and CPD57-treated mice also survived longer than untreated animals.<\/p>\n<p>ETH Zurich Is Seeking a Partner to Advance CPD10 Toward Human Development<\/p>\n<p class=\"wp-block-paragraph\">With the basic research now complete and a patent application filed, Quitterer and ETH Zurich are actively looking for a pharmaceutical company to take the next steps. The motivation, she says, is clear. \u201cCurrent medications do not cure the disease, but rather, at most, delay its progression by several months,\u201d Quitterer says. \u201cThat\u2019s why it\u2019s so important that we\u2019ve now identified a new target protein in the form of GRK2, as well as an active ingredient that operates via GRK2 and therefore via a different mechanism than existing Alzheimer\u2019s drugs.\u201d<\/p>\n<p class=\"wp-block-paragraph\">All animal experiments were conducted in genetically engineered mice, and results in mouse models frequently fail to translate to people. Human tissue data from a small number of patients serve as supporting observations, not clinical proof.<\/p>\n<p class=\"wp-block-paragraph\">Still, a compound that targets a new mechanism, crosses into the brain, slows <a href=\"https:\/\/studyfinds.com\/reusing-cooking-oil-brain-health\/\" type=\"post\" id=\"126636\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">neurodegeneration<\/a>, extends survival, and appears to slow aging in mice gives researchers an unusually specific thread to pull in a disease that has no cure.<\/p>\n<p class=\"wp-block-paragraph\">Disclaimer: This article is based on peer-reviewed animal research and information from an institutional press release. Findings from mouse studies do not always translate to humans, and neither CPD10 nor CPD57 has been tested in human clinical trials. This content is for informational purposes only and is not intended as medical advice.<\/p>\n<p>Paper Notes<\/p>\n<p>Limitations<\/p>\n<p class=\"wp-block-paragraph\">Conducted entirely in genetically engineered mouse models of Alzheimer\u2019s disease, this study carries the standard caveat that mouse models do not fully replicate human disease and results do not always translate. Human brain tissue findings come from a small number of patients with \u201cdementia likely due to AD\u201d rather than pathologically confirmed cases; the authors themselves note this small sample size as a limitation and flag that treatment data need to be translated to human patients before conclusions about clinical applicability can be drawn. No human clinical trial or safety or efficacy data for CPD10 or CPD57 in people exist. An additional open question acknowledged by the authors is whether the aggregated protein on mitochondria is the primary driver of neurodegeneration, or whether the loss of functional GRK2 in the cell caused by that aggregation is an equally important factor.<\/p>\n<p>Funding and Disclosures<\/p>\n<p class=\"wp-block-paragraph\">Funding was provided in part by grants ETH-18 14-2, SNSF140679, and SNSF169354 to lead author Ursula Quitterer. CPD10 and CPD57 are covered by ETH Zurich patent applications.<\/p>\n<p>Publication Details<\/p>\n<p class=\"wp-block-paragraph\">Authors: Joshua Abd Alla, Alexander Perhal, Xuebin Fu, Andreas Langer, Yasser el Faramawy, and Ursula Quitterer | Affiliations: Molecular Pharmacology, ETH Zurich, Switzerland; Department of Pharmaceutical Sciences, University of Vienna, Austria; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Medical Research Center (MRC), Ain Shams University Hospitals, Cairo, Egypt; Institute of Pharmacology and Toxicology, University of Zurich, Switzerland | Journal: <a href=\"https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(26)00124-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126001242%3Fshowall%3Dtrue\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Cell Reports Medicine<\/a>, Volume 7, Article 102707 | Publication Date: April 21, 2026 | Paper Title: \u201cAnalysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models\u201d | DOI: https:\/\/doi.org\/10.1016\/j.xcrm.2026.102707 | Access: Open access under CC BY license<\/p>\n","protected":false},"excerpt":{"rendered":"(Credit: \u00a9 Robert Kneschke | Dreamstime.com) New Alzheimer\u2019s Drug Candidate Targets a Different Mechanism Than Existing Treatments In&hellip;\n","protected":false},"author":2,"featured_media":81982,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[6],"tags":[3747,10078,15909,42291,3756,15910,51],"class_list":["post-81981","post","type-post","status-publish","format-standard","has-post-thumbnail","category-zurich","tag-aging","tag-alzheimers","tag-alzheimers-disease","tag-anti-aging","tag-brain","tag-dementia","tag-zurich"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116734550081372431","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=81981"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81981\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/81982"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=81981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=81981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=81981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}